2023 - Research.com Biology and Biochemistry in Switzerland Leader Award
Genetics, Gene, Allele, Molecular biology and Drug metabolism are his primary areas of study. His study in the field of Arylamine N-acetyltransferase, Locus, Point mutation and Exon also crosses realms of Pseudogene. His Allele research is multidisciplinary, incorporating elements of Mephenytoin, CYP2C19, Phenotype, Genotyping and Genetic variation.
He has included themes like Mutant and Restriction fragment length polymorphism in his Molecular biology study. His research integrates issues of Cytochrome, Xenobiotic and Cytochrome P450 in his study of Drug metabolism. His study focuses on the intersection of Cytochrome and fields such as Antibody with connections in the field of Microsome.
Urs A. Meyer spends much of his time researching Biochemistry, Genetics, Cytochrome P450, Gene and Molecular biology. He interconnects Isozyme and Pharmacology in the investigation of issues within Cytochrome P450. His Locus, Gene expression, Exon and Point mutation study, which is part of a larger body of work in Gene, is frequently linked to Pseudogene, bridging the gap between disciplines.
Urs A. Meyer combines subjects such as Complementary DNA, Nucleic acid sequence, Peptide sequence and Restriction enzyme with his study of Molecular biology. His Microsome study integrates concerns from other disciplines, such as Hydroxylation, Bufuralol, Sparteine, Stereochemistry and Cytochrome. His Allele study combines topics in areas such as CYP2D6, Genotyping and Genetic variation.
His scientific interests lie mostly in Biochemistry, Pregnane X receptor, Constitutive androstane receptor, Nuclear receptor and Pharmacology. His Constitutive androstane receptor research incorporates themes from Retinoid X receptor, Drug metabolism, Xenobiotic and Receptor, Internal medicine. His study in Nuclear receptor is interdisciplinary in nature, drawing from both AMP-activated protein kinase, Signal transduction, Protein kinase A and Transactivation.
His studies deal with areas such as Toxicology, Computational biology, Toxicity and In vivo as well as Pharmacology. His studies in Cytochrome P450 integrate themes in fields like Molecular biology and Heme. In his study, which falls under the umbrella issue of Pharmacogenetics, Genetics is strongly linked to Therapeutic failure.
Urs A. Meyer mostly deals with Biochemistry, Pregnane X receptor, Constitutive androstane receptor, Nuclear receptor and Cytochrome P450. His Pregnane X receptor research incorporates elements of Farnesoid X receptor, Retinoid X receptor, Drug metabolism and Transactivation. His research integrates issues of Liver X receptor, Liver X receptor alpha, Xenobiotic and Liver X receptor beta in his study of Retinoid X receptor.
His research in Transactivation intersects with topics in Pharmacology and In vivo. His Nuclear receptor study combines topics from a wide range of disciplines, such as AMP-activated protein kinase, AMPK, Protein kinase A, Receptor and Signal transduction. His work carried out in the field of Cytochrome P450 brings together such families of science as ALAS1, Hemeprotein, Heme and Enzyme inducer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
S. M. F. De Morais;G. R. Wilkinson;J. Blaisdell;K. Nakamura.
Journal of Biological Chemistry (1994)
IDENTIFICATION OF A NEW GENETIC DEFECT RESPONSIBLE FOR THE POLYMORPHISM OF (S)-MEPHENYTOIN METABOLISM IN JAPANESE
S. M. F. De Morais;G. R. Wilkinson;J. Blaisdell;U. A. Meyer.
Molecular Pharmacology (1994)
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.
F J Gonzalez;R C Skoda;S Kimura;M Umeno.
Nature (1988)
Pharmacogenetics and adverse drug reactions
Urs A Meyer.
The Lancet (2000)
Molecular mechanisms of genetic polymorphisms of drug metabolism.
Urs A. Meyer;Ulrich M. Zanger.
Annual Review of Pharmacology and Toxicology (1997)
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
T Kronbach;D Mathys;M Umeno;F J Gonzalez.
Molecular Pharmacology (1989)
Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.
M Heim;U.A Meyer.
The Lancet (1990)
Induction of Drug Metabolism: The Role of Nuclear Receptors
Christoph Handschin;Urs A. Meyer.
Pharmacological Reviews (2003)
Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.
M. Blum;D.M. Grant;W. McBRIDE;M. Heim.
DNA and Cell Biology (1990)
Nomenclature for human CYP2D6 alleles.
A K Daly;J Brockmoller;F Broly;M Eichelbaum.
Pharmacogenetics (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Hohenheim
University of Tübingen
National Institutes of Health
University Hospital of Basel
Robert Bosch (Germany)
Heidelberg University
University of California, San Diego
National Institutes of Health
Erasmus University Rotterdam
University of Montpellier
IBM (United States)
PayPal (United States)
University of Leon
King's College London
University of British Columbia
University of Rochester
University of Glasgow
Jiangnan University
University of Zurich
University of California, Santa Barbara
University of South Carolina
Paracelsus Medical University
The University of Texas at Dallas
Centers for Disease Control and Prevention
University of Amsterdam
Indiana University